Geographic Atrophy
Geographic Atrophy (GA) is a progressive eye disease that causes the gradual loss of retinal cells, leading to vision loss. It is often associated with age-related macular degeneration and can result in blind spots in your vision.
Geographic Atrophy: Tinlarebant Treatment Study
We are exploring whether Tinlarebant can slow the growth of lesions in people with geographic atrophy and improve their vision. This study compares the new treatment to a placebo to assess its effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 60 and 85 years old?
- Do you have a confirmed diagnosis of geographic atrophy (GA) with atrophic lesions in one or both eyes?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications that are known to be harmful to the eyes, like retinotoxic drugs?
- Have you had any major eye surgery in the last 3 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Lbs-008
Tinlarebant
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Fakultni Nemocnice Ostrava
Ophtalmology
Hlučín, Czechia
Axon Clinical s.r.o.
Ophtalmology
Prague, Czechia
Fakultni Thomayerova nemocnice
Ophtalmology
Prague, Czechia
Sponsor: Belite Bio Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.